Is Hormone Replacement Safe? Separating Fact From Fiction
Patients frequently come to our clinic asking, “Is hormone replacement safe? I see all kinds of things on social media. Can you help me make sense of it all?” It is easy to feel overwhelmed by conflicting online claims that paint hormone therapy as either incredibly dangerous or a miraculous cure-all. The truth is much more straightforward: modern bioidentical hormone replacement therapy is a safe and effective option for many individuals when managed correctly. When you work with a specifically trained provider at Lone Star Center for Health and Wellness who performs a thorough evaluation, prescribes the precise dose your body needs, and monitors your progress, hormone optimization can safely improve your quality of life. For more information, contact us or request an appointment online. We are conveniently located at 8233 Fredericksburg Rd, San Antonio, TX 78229.
Question: Is hormone replacement safe? I see all kinds of things on social media. Can you help me make sense of it all?
Social media can make hormone therapy sound either completely dangerous or like a cure-all. The reality is more straightforward: modern bioidentical hormone replacement and optimization can be a safe and effective option for many people when it is done correctly—by a provider specifically trained and experienced in bioidentical hormone replacement and optimization who performs a thorough evaluation, uses the right hormones at the right dose, and provides proper monitoring.
A major source of the fear comes from the 2002 Women’s Health Initiative (WHI) study. That trial used older synthetic hormone mixtures that included equine (horse-derived) estrogen formulations combined with a synthetic progestin. Those are not the same as the bioidentical hormones (molecules identical to those the body produces) used in many practices today. The average age of participants was about 63, and many were well past menopause. Relative risks were heavily emphasized over the much smaller absolute risks, and the findings were broadly applied in ways the study design did not fully support. Later analyses and critiques have highlighted these limitations—including the formulations used, the age and timing of initiation in participants, and how results were presented—showing that the original interpretations overstated risks for younger women closer to menopause and do not fully apply to current bioidentical approaches. The findings have been substantially refined, and many of the broad warnings that followed do not hold up for appropriately selected patients using modern therapy.
Today, many clinicians use bioidentical options such as estradiol, micronized progesterone, and testosterone. These are available in FDA-approved forms (patches, gels, capsules) as well as customized compounded preparations to meet specific needs. When therapy is matched to the individual—based on symptoms, labs, medical history, and ongoing follow-up—the benefits of relieving hot flashes, night sweats, sleep issues, vaginal dryness, low libido, low energy, brain fog, and other symptoms can meaningfully improve quality of life. Working with a provider specifically trained and experienced in bioidentical hormone replacement therapy helps reduce symptoms, improve quality of life, and minimize risk through careful selection, dosing, and monitoring.
Safe when done correctly” means more than just the type of hormone. It includes:
• A provider specifically trained and experienced in bioidentical hormone replacement therapy
• A thorough medical evaluation before starting
• Identifying the optimal dose and preferred route for the person
• Regular monitoring and adjustments
• Shared decision-making with a knowledgeable clinician specifically trained in bio-identical hormone replacement and optimization therapy.
Hormone therapy is not risk-free for everyone, and social media rarely captures the nuances of individual risk. The best way to sort through the noise is a personalized conversation with a provider who understands current options, including bioidentical approaches, and can help you decide what makes sense for your health and goals.
Have a question for Brenda? Send it to us—we’re happy to help.
Brenda is highly trained in bioidentical hormone replacement therapy and optimization, with over a decade of experience helping patients from all walks of life regain their zeal. She is considered an expert in bioidentical hormone replacement therapy and optimization.
References
Estradiol (E2) — Women (Menopausal Symptoms & Quality of Life)
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023). Management of menopausal symptoms: A review. JAMA, 329(5), 405–420. https://doi.org/10.1001/jama.2022.24140
Foschi, M., Groccia, G., Rusce, M. L., Medaglia, C., Aio, C., Sponzilli, A., Setti, V., Battipaglia, C., & Genazzani, A. D. (2025). Estradiol and micronized progesterone: A narrative review about their use as hormone replacement therapy. Journal of Clinical Medicine, 14(20), Article 7328. https://doi.org/10.3390/jcm14207328
Santoro, N., Allshouse, A., Neal-Perry, G., Pal, L., Lobo, R. A., Naftolin, F., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Dowling, N. M., Dunn, M., Gleason, C. E., Hodis, H. N., Isaac, B., Magnani, M., Manson, J. E., Miller, V. M., Taylor, H. S., Wharton, W., Wolff, E., Zepeda, V., & Harman, S. M. (2017). Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: The Kronos Early Estrogen Prevention Study. Menopause, 24(3), 238–246. https://doi.org/10.1097/GME.0000000000000756
Simon, J. A., Kaunitz, A. M., Kroll, R., Graham, S., Bernick, B., & Mirkin, S. (2019). Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause, 26(5), 506–512. https://doi.org/10.1097/GME.0000000000001271
Zhang, G.-Q., Chen, J.-L., Luo, Y., Mathur, M. B., Anagnostis, P., Nurmatov, U., Talibov, M., Zhang, J., Hawrylowicz, C. M., Lumsden, M. A., Critchley, H., Sheikh, A., Lundbäck, B., Lässer, C., Kankaanranta, H., Lee, S. H., & Nwaru, B. I. (2021). Menopausal hormone therapy and women’s health: An umbrella review. PLOS Medicine, 18(8), Article e1003731. https://doi.org/10.1371/journal.pmed.1003731
Testosterone — Men (Including Late-Onset / Age-Related Hypogonadism)
Bhasin, S., & Snyder, P. J. (2025). Testosterone treatment in middle-aged and older men with hypogonadism. The New England Journal of Medicine, 393(6), 581–591. https://doi.org/10.1056/NEJMra2404637
Corona, G., Torres, L. O., & Maggi, M. (2020). Testosterone therapy: What we have learned from trials. The Journal of Sexual Medicine, 17(3), 447–460. https://doi.org/10.1016/j.jsxm.2019.11.270
Diem, S. J., Greer, N. L., MacDonald, R., McKenzie, L. G., Dahm, P., Ercan-Fang, N., Estrada, A., Hemmy, L. S., Rosebush, C. E., Fink, H. A., & Wilt, T. J. (2020). Efficacy and safety of testosterone treatment in men: An evidence report for a clinical practice guideline by the American College of Physicians. Annals of Internal Medicine, 172(2), 105–118. https://doi.org/10.7326/M19-0830
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Jr., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., … Nissen, S. E. (2023). Cardiovascular safety of testosterone-replacement therapy. The New England Journal of Medicine, 389(2), 107–117. https://doi.org/10.1056/NEJMoa2215025
Qaseem, A., Horwitch, C. A., Vijan, S., Etxeandia-Ikobaltzeta, I., & Kansagara, D. (2020). Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Annals of Internal Medicine, 172(2), 126–133. https://doi.org/10.7326/M19-0882
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., Ensrud, K. E., Lewis, C. E., Farrar, J. T., Cella, D., Rosen, R. C., Pahor, M., Crandall, J. P., Molitch, M. E., Cifelli, D., … Ellenberg, S. S. (2016). Effects of testosterone treatment in older men. The New England Journal of Medicine, 374(7), 611–624. https://doi.org/10.1056/NEJMoa1506119
Testosterone — Women (HSDD / Low Sexual Desire)
Achilli, C., Pundir, J., Ramanathan, P., Sabatini, L., Hamoda, H., & Panay, N. (2017). Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: A systematic review and meta-analysis. Fertility and Sterility, 107(2), 475–482.e15. https://doi.org/10.1016/j.fertnstert.2016.10.028
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666. https://doi.org/10.1210/jc.2019-01603
Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology, 7(10), 754–766. https://doi.org/10.1016/S2213-8587(19)30189-5
Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., Park, K., Stuenkel, C. A., Traish, A. M., & Vignozzi, L. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. The Journal of Sexual Medicine, 18(5), 849–867. https://doi.org/10.1016/j.jsxm.2020.10.009
DISCLAIMER
This message is for patient education at Lone Star Center for Health & Wellness. It summarizes published trial findings on hormone replacement and optimization (including estradiol and testosterone). It is not a prescription, not a complete list of risks, and not a substitute for an individual visit. Hormone therapy is not appropriate for everyone and requires clinician review of personal and family medical history (including cancer, cardiovascular disease, clotting disorders, and other conditions). Risks and benefits vary by the type of hormone, dose, route, and the individual patient. Always review your history, other medicines, symptoms, and goals with a provider trained in hormone therapy before starting, changing, or stopping treatment.
Send Text
How May I Help You?